Ken Nelson, Head of Digital Health, Diagnostics, & Monitoring, Biotronik

CEO, Founder, and proud member and connector in the Medtech ecosystem. As CEO of LSI, a global healthcare market research and advisory firm, I support startups, investors, strategics, and professional service companies by providing independent market data/insights to help inform their decisions. I aim to leverage my deep network to connect investors with innovators tackling the world's biggest healthcare challenges. Proud to be the Founder of the US and European Emerging Medtech Summit events which have become the go-to investment & partnering conferences in Medtech. I've managed over 200 consulting and due diligence engagements with companies such as J&J, Medtronic, Abbott, Siemens Healthineers, General Electric, amongst others. Proud and honored to serve as a Board Advisor to several early/growth-stage companies and to advise private investors, family offices, PE firms, and SPACs to identify new opportunities in healthcare.

Over the past 10 years, I have led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries, playing a significant role in building the teams and cultures for 3 of the top 4 market share players, including #1 (BioTelemetry), #2 (iRhythm), and #4 (Bardy Diagnostics).

Overall, I’m a 20 year digital health, medical device, and remote monitoring innovator with successful senior leadership experience ranging from a Fortune 500 company (Boston Scientific) to a medium sized #1 market share (Biotelemetry, acquisition by Philips for $2.8 Billion in December '20) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which was acquired by HillRom (Bardy Diagnostics) in August '21 for what will end up being $400M+ after milestone payments.

Along the way I accomplished the following achievements most recently:

• Built the teams, culture, and infrastructure, as well as developed the strategies and executed on the business plans to help drive global commercialization efforts of a disruptive cardiac monitoring patch (CAM Patch), resulting in multiple rounds of venture capital, including a $35M+ round in April 2019.
• Raised significant shareholder value as well as a combined $100M+ in venture capital funding for iRhythm and Bardy Diagnostics, leading successful commercialization efforts for both by focusing on recruiting the right people, building the right culture, and developing strategic plans that led to explosive growth.
• Led Biotelemetry to profitability for the first time ever, and grew them to the #1 market share player, in part by developing a winning team and culture to successfully grow revenue for 18 consecutive quarters from $111M in revenue in 2012 to $208M in revenue in 2016, exceeding quota in all 18 quarters.
• Drove successful acquisitions of competitors and emerging technology, as well as developed impactful strategic partnerships, all of which added to the explosive growth of these companies.